Lonza Group (LZAGY) Stock Price, News & Analysis

Company Overview

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $67.90 to $68.34
• 50-Day Range: $57.21 to $72.87
• 52-Week Range: $52.23 to $73.29
• Volume: 17,187 shs
• Average Volume: 92,108 shs
• Market Capitalization: $49.25 billion
• P/E Ratio: N/A
• Dividend Yield: 0.15%
• Price Target: N/A
• Consensus Rating: Strong Buy

LZAGY Stock Analysis - Frequently Asked Questions

How have LZAGY shares performed this year?

Lonza Group's stock was trading at $58.78 at the beginning of 2025. Since then, LZAGY stock has increased by 16.0% and is now trading at $68.19.
View the best growth stocks for 2025 here.

Does Lonza Group have any subsidiaries?

Lonza Group subsidiaries include these companies: Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and others.

How do I buy shares of Lonza Group?

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 5/30 Dividend: 5/14/2025
• Record date for 5/30 Dividend: 5/15/2025
• Today: 5/24/2025
• Dividend Payable: 5/30/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Tobacco products
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LZAGY
• CIK: 1446711
• Web: www.lonza.com
• Phone: (161) 316-8111
• Fax: 41-61-316-9111
• Employees: 18,000
• Year Founded: 1897

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 36.27
• P/E Growth: 2.01
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 1.52
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $7.47 billion
• Price / Sales: 6.59
• Cash Flow: $2.10 per share
• Price / Cash Flow: 32.54
• Book Value: $14.76 per share
• Price / Book: 4.62

Miscellaneous

• Outstanding Shares: 722,262,000
• Free Float: 721,756,000
• Market Cap: $49.25 billion
• Optionable: Not Optionable
• Beta: 1.23